ArticleAdvanced fiber materials2026
Translational Potential of an Electrospun Polycaprolactone Scaffold for Anterior Cruciate Ligament Reconstruction.
Article in Advanced fiber materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Multi-biomimetic poly(amino acid)-based Janus membrane integrating barrier and osteoinductive functions for cranial bone regeneration.Materials today. Bio · 2026Article
- Anterior Cruciate Ligament Tissue Engineering: Biological Principles, Engineered Substitutes, and Preclinical Outcomes.Bioengineering (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
Anterior cruciate ligament (ACL) injuries are common and often require surgical reconstruction. Autografts remain the clinical standard for ACL reconstruction (ACLR) but are limited by donor site morbidity, inconsistent outcomes, and supply constraints. Here, we report the development of electrospun ligament (ES-Lig), a fully degradable, electrospun scaffold composed of poly(ε-caprolactone) (PCL) designed to mimic the extracellular matrix (ECM) of the native ACL. A scalable manufacturing process was established, incorporating electrospinning, filament stretching, alignment, and braiding. ES-Lig demonstrated controlled in vitro degradation over 12 months while retaining sufficient mechanical strength for early-stage healing. Mechanical characterisation revealed tensile properties and fixation stability comparable to autografts. In vitro biocompatibility was confirmed through cytotoxicity assays, patient-derived ACL explants, and direct cell growth onto the material. In an ovine ACLR model, ES-Lig enabled functional recovery, tissue infiltration throughout its length, and joint stability within 10 weeks post-implantation. Histological and imaging analyses confirmed graft-bone integration, vascularisation, and early ligamentisation. These findings establish ES-Lig as a promising, clinically translatable scaffold for next-generation ACL repair. Graphical abstract: Supplementary Information: The online version contains supplementary material available at 10.1007/s42765-025-00632-8.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.